Mitochondrial connection to Alzheimer's disease and heart failure

Anupriya Sinha1, Natasha Jaiswal2, Pooja Jadiya2,3

  • 1Department of Cardiovascular Medicine, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA.

Insights

The brain and heart are linked; problems in one affect the other. Mitochondrial dysfunction is a key factor in both Alzheimer's disease (AD) and cardiovascular diseases (CVDs), suggesting new therapy targets.

Area of Science:

  • Neuroscience
  • Cardiology
  • Mitochondrial Biology

Background:

  • The brain and heart exhibit a strong interdependence, where dysfunction in one organ system can precipitate issues in the other.
  • Cardiovascular diseases (CVDs), such as heart failure, can compromise cerebral blood flow, leading to cognitive impairment and elevated dementia risk.
  • Alzheimer's disease (AD), characterized by specific neuropathological hallmarks, has been observed to negatively affect cardiac function.

Purpose of the Study:

  • To explore the intricate relationship between brain and heart health.
  • To investigate the shared role of mitochondrial dysfunction in the pathogenesis of both Alzheimer's disease and cardiovascular diseases.
  • To highlight the therapeutic potential of targeting mitochondrial pathways for co-treating neurodegenerative and cardiovascular conditions.

Main Methods:

  • Review of existing literature on the interplay between cardiovascular and neurological systems.
  • Analysis of shared molecular and cellular mechanisms, focusing on mitochondrial function.
  • Examination of the impact of AD and CVD on organ-specific pathologies.

Main Results:

  • Evidence indicates that impaired cerebral blood flow in CVDs contributes to cognitive decline and dementia.
  • Alzheimer's disease pathology is associated with detrimental effects on cardiac function.
  • Mitochondrial dysfunction emerges as a critical common pathway, exacerbating both neurodegeneration in AD and cardiac issues in CVDs.

Conclusions:

  • The brain-heart axis is a critical determinant of overall health, with bidirectional influences.
  • Mitochondrial dysfunction is a pivotal shared mechanism underlying Alzheimer's disease and cardiovascular diseases.
  • Targeting mitochondrial health presents a promising therapeutic avenue for simultaneously addressing neurodegenerative and cardiovascular diseases, particularly in an aging population.

Related Concept Videos

Mitochondria01:37

Mitochondria

Mitochondria are eukaryotic cellular organelles that are known to produce energy through a process called oxidative phosphorylation. Besides their primary function, mitochondria are involved in various cellular processes, including cell growth, differentiation, signaling, metabolism, and senescence. Age-related changes cause a decline in mitochondrial quality and integrity due to increased mitochondrial mutations and oxidative damage. Thus, aging can severely impact mitochondrial functions,...
21.4K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
19.6K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.4K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.6K